FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
December 31, 2021
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, \
is pleased to announce that it has entered into a revolving line-of-credit loan agreement dated as
of December 18, 2021, representing additional available funding as needed of up to $230,000. The terms of
the loan require that any borrowed amounts be repaid by the Company, along with interest at 8% per year,
by no later than December 18, 2023. The loan is secured against the assets of the Company.
The Company has the right to repay any loan amounts outstanding at any time, in whole or in installments,
without penalty. In addition, the lender may elect to convert the loan into common shares of the Company at
a price per share equal to the "discounted market price" under the policies of the TSX Venture Exchange. Any
conversion of debt into shares will be subject to applicable securities laws and approval of the TSX Venture
The Company also announces the proposed issuance of shares for debt. Under debt settlement agreements,
the Company will issue an aggregate of 463,740 common shares of the Company ("Shares") to certain
directors, a former director and a former officer of the Company at a deemed price of $0.05 per Share. The
Shares will be provided to settle debt for services provided to the Company and will be subject to a four month
hold period in accordance with applicable securities laws. The issuance of the Shares is subject to receipt of
approval from the TSX Venture Exchange.
The Company also granted 62,500 stock options to a director of the Company, each option exercisable at
$0.05 per Share for five years from the date of grant and vesting immediately. The options are subject to the
provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable
Directors of the Company participated in the debt settlement and a director of the Company received stock
options, each of which is considered to be a "related party transaction" as defined under Multilateral
Instrument 61-101 ("MI 61-101"). Each transaction is exempt from the formal valuation and minority
shareholder approval requirements of MI 61-101 as the fair market value of each transaction does not exceed
25% of the market capitalization of the Company, as determined in accordance with MI 61-101.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company's websites at
www.cardiocommsolutions.com and www.theheartcheck.com.
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.